|
Wednesday, November 16, 2016
Print Current Day:
 |
|
| SESSION 23 SCHEDULE | |
|
Wednesday
SESSION 23:
LOWER EXTREMITY OCCLUSIVE DISEASE MANAGEMENT – HOT TOPICS AND NEW DEVELOPMENTS
Moderators:Enrico Ascher, MD / Craig M. Walker, MD
|
|
| x | |
| 6:40 AM - 6:45 AM | Some CLI Patients Are Better Managed Without Revascularization: Which Ones |
| Presenter(s):Frank J. Criado, MD, FACS, FSVM | |
| View Slides in PDF | |
| 6:46 AM - 6:51 AM | What Is The Optimal Waiting Period After Endo Or Open Revascularization To Perform Local Procedures For Foot Infection, Gangrene Or Necrosis |
| Presenter(s):Wayne J. Caputo, DPM | |
| View Slides in PDF | |
| 6:52 AM - 6:57 AM | Tips And Tricks For Achieving Healing And Limb Salvage With Ischemic Heel Ulcers And Gangrene: The Achilles Tendon And Part Of The Os Calcis May Have To Go |
| Presenter(s):Palma M. Shaw, MD / Frank J. Veith, MD | |
| View Slides in PDF | |
| 6:58 AM - 7:03 AM | Delay In Revascularization May Lead To Disaster In Diabetic Patients With Diabetic Foot Ulcers And Infection: What Is The Optimal Treatment Sequence For Drainage And Revascularization |
| Presenter(s):Katariina M. Noronen, MD | |
| View Slides in PDF | |
| 7:04 AM - 7:09 AM | Single vs. Multivessel Tibial Interventions For CLI: A Large Single Institution Study Shows Multivessel Treatment Offers No Benefit |
| Presenter(s):Marc L. Schermerhorn, MD | |
| View Slides in PDF | |
| 7:10 AM - 7:15 AM | DEBATE: When Is CLI Best Treated By Endovascular Techniques And When By Open Bypass: The Latter Has An Important Role In Many Patients (What Percent) |
| Presenter(s):Francesco Spinelli, MD | |
| View Slides in PDF | |
| 7:16 AM - 7:21 AM | DEBATE: All CLI Patients Can And Should Be Treated By An Endo-First Approach: Few (What Percent) Will Require Open Surgical Revascularization At Any Point In Their Course |
| Presenter(s):Andrej Schmidt, MD | |
| View Slides in PDF | |
| 7:22 AM - 2:27 AM | True Lumen vs. Subintimal Routes For Lower Extremity Interventions Above-The-Knee (ATK) And Below-The-Knee (BTK): What Is Durability Of BTK Interventions |
| Presenter(s):Marco G. Manzi, MD | |
| View Slides in PDF | |
| 7:28 AM - 7:33 AM | Value Of The Bullfrog Balloon Catheter (Mercator) For Local Adventitial Drug Delivery Into Occlusive Lesions: Dexamethasone And Paclitaxel Can Be Injected: Results Of The DANCE And LIMBO Trials |
| Presenter(s):George L. Adams, M.D. | |
| View Slides in PDF | |
| 7:34 AM - 7:39 AM | Importance Of Foot And Ankle Occlusive Lesions In CLI With Gangrene: When And How To Treat It: Principles, Techniques And Limitations |
| Presenter(s):Roberto Ferraresi, MD | |
| View Slides in PDF | |
| 7:40 AM - 7:46 AM | Panel Discussion |
| END OF SESSION 23 | |
| SESSION 24 SCHEDULE | |
|
Wednesday
SESSION 24:
MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE – NEW DEVELOPMENTS AND HOT TOPICS RELATING TO STENTS
Moderators:Giancarlo Biamino, MD, PhD / Kenneth Ouriel, MD, MBA
|
|
| x | |
| 7:46 AM - 7:51 AM | The Best Special Wires, Sheaths, Catheters And Balloons For Treating Perimalleolar And Pedal Occlusive Lesions: What’s New In Tools For Crossing Total Occlusions |
| Presenter(s):Craig M. Walker, MD | |
| View Slides in PDF | |
| THE SUPERA BIOMIMETIC INTERWOVEN STENT | |
| 7:52 AM - 7:57 AM | 5-Year Results With The Supera Stent Are Better Than Those With Bare Metal Stents (BMSs) And Drug Coated Balloons (DCBs) In A Propensity Matched Analysis |
| Presenter(s):Dierk Scheinert, MD / Andrej Schmidt, MD / Sabine Steiner, MD | |
| View Slides in PDF | |
| 7:58 AM - 8:03 AM | Economic Considerations With The Supera Stent For Treating SFA Lesions: How Does It Compare With Plain Old Balloon Angioplasty (POBA), BMSs, Drug Eluting Stents (DESs) And Drug Coated Balloons (DCBs) |
| Presenter(s):Brian G. DeRubertis, MD | |
| View Slides in PDF | |
| 8:04 AM - 8:09 AM | Supera Stenting Of Lesions Seem To Restore Distal Blood Flow Better Than Other Endovascular Treatments And As Well As A Bypass |
| Presenter(s):Steven Kum, MD | |
| View Slides in PDF | |
| THE ZILVER PTX DES | |
| 8:10 AM - 8:15 AM | New Findings From The RCT Of The Zilver PTX Stent vs. PTA And Bare Metal Stents: Interesting Findings From Subanalyses And 5-Year Result Show Widening Benefits From The DES |
| Presenter(s):Gary M. Ansel, MD / Michael D. Dake, MD | |
| View Slides in PDF | |
| 8:16 AM - 8:21 AM | RCT Comparing Zilver PTX DES And Surgical Bypass For Long Fempop Lesions Suggest Better Results In The DES Arm: Is It Due To Differences In The Method Of Patency Assessment: The ZILVERPASS Trial |
| Presenter(s):Koen Deloose, MD / Marc Bosiers, MD / Patrick Peeters, MD | |
| View Slides in PDF | |
| 8:22 AM - 8:27 AM | Update On The 2-Year Results Of The Eluvia DES From Boston Scientific For SFA Lesions: Why Are The Results So Superior To POBA: From The MAJESTIC Trial: What Is Happening With The IMPERIAL Trial Comparing Eluvia And Zilver PTX DESs |
| Presenter(s):Stefan Müller-Hülsbeck, MD | |
| View Slides in PDF | |
| BIORESORBABLE STENTS | |
| 8:28 AM - 8:33 AM | Favorable 1-2 Year Results With The Abbott Balloon Expandable Bioresorbable Drug Eluting Stent For BTK Occlusive Lesions: Do The Lesions Regress: The ABSORB BTK Trial |
| Presenter(s):Ramon L. Varcoe, MS, PhD, FRACS | |
| View Slides in PDF | |
| 8:34 AM - 8:39 AM | Status Of Other Bioabsorbable Scaffolds (Stents) For Treating Peripheral Arterial Lesions Including 3-Year Results Of The ESPRIT Trial |
| Presenter(s):Johannes Lammer, MD | |
| View Slides in PDF | |
| DESS BELOW-THE-KNEE | |
| 8:40 AM - 8:45 AM | DESs (Sirolimus) Are Better Than POBA For Treating CLI Caused By Infrapopliteal Lesions: Wound Healing And Quality Of Life Are Improved: The ACHILLES Trial |
| Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
| View Slides in PDF | |
| 8:46 AM - 8:51 AM | 3 RCTs Show That DESs Have Value In Treating Long And Short BTK Occlusive Lesions: When Should They Be Used: A US Perspective |
| Presenter(s):Robert A. Lookstein, MD, FSIR, FAHA | |
| View Slides in PDF | |
| 8:52 AM - 8:58 AM | Panel Discussion |
| END OF SESSION 24 | |
| SESSION 25 SCHEDULE | |
|
Wednesday
SESSION 25:
MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT: DEALING WITH CALCIFICATION; ATHERECTOMY
Moderators:Gary M. Ansel, MD / James F. McKinsey, MD
|
|
| x | |
| 8:58 AM - 9:03 AM | When Are POBA And BMSs Adequate Treatment For Fempop Lesions And When Should Other Modalities Like Atherectomy Or DCBs Be Used |
| Presenter(s):Krishna J. Rocha-Singh, MD | |
| View Slides in PDF | |
| 9:04 AM - 9:09 AM | DEBATE: A Skeptic’s View On The Value Of Atherectomy |
| Presenter(s):Frank J. Criado, MD, FACS, FSVM | |
| View Slides in PDF | |
| 9:10 AM - 9:15 AM | DEBATE: New Developments In Atherectomy Indicate A Promising Future: The DEFINITIVE AR Trial Shows That Atherectomy Plus DCBs Have Value: When Are They Indicated |
| Presenter(s):Ulrich Beschorner, MD / Thomas Zeller, MD | |
| View Slides in PDF | |
| 9:16 AM - 9:21 AM | Update On Atherectomy For Calcified Lesions: What Devices Are Best: When Should They Be Used With DCBs: Value Of Lesion Prep: Precautions And Midterm Results |
| Presenter(s):Lawrence A. Garcia, MD | |
| View Slides in PDF | |
| 9:22 AM - 9:27 AM | When And How To Use Distal Embolic Protection Devices During Lower Extremity Interventions |
| Presenter(s):D. Christopher Metzger, MD | |
| View Slides in PDF | |
| 9:28 AM - 9:33 AM | Long Complex SFA Lesions Are Poorly Treated With Stents And DCBs: Atherectomy And DCBs Are The Treatment Of Choice: Which Device Is Best And Precautions |
| Presenter(s):Brian G. DeRubertis, MD | |
| View Slides in PDF | |
| 9:34 AM - 9:39 AM | Patterns Of Wall Calcification In Lower Extremity Arteries And How They Impact On Endovascular Treatments: Is There A Grading System And How To Cross Calcified CTOs |
| Presenter(s):Jihad A. Mustapha, MD | |
| View Slides in PDF | |
| 9:40 AM - 9:45 AM | What Is The Best Treatment For Long Or Calcified SFA Lesions Causing CLI: The Role Of DCBs, DESs, Atherectomy And Supera BMSs |
| Presenter(s):Koen Deloose, MD / Marc Bosiers, MD | |
| View Slides in PDF | |
| 9:46 AM - 9:51 AM | Value Of Atherectomy And DCBs In The Treatment Of Popliteal Occlusive Lesions: Is Distal Embolic Protection Possible |
| Presenter(s):Marco G. Manzi, MD | |
| View Slides in PDF | |
| 9:52 AM - 9:57 AM | Foot Artery Interventions: When And How Should They Be Attempted; What Are The Results Of Treatment In Terms Of Treated Lesion Patency And Wound Healing At 1, 2 And 3 Years Or Longer |
| Presenter(s):Roberto Ferraresi, MD | |
| View Slides in PDF | |
| 9:58 AM - 10:04 AM | Panel Discussion |
| 10:04 AM - 10:13 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 25 | |
| SESSION 26 SCHEDULE | |
|
Wednesday
SESSION 26:
MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE: NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs); DEALING WITH COMPLEX LESIONS AND TRIALS
Moderators:Michael S. Conte, MD / John R. Laird, MD
|
|
| x | |
| 10:13 AM - 10:18 AM | Basic Principles And Constraints Of Various Drug Delivery Systems: They Are Not Simple And Details Matter: Why Leaving No Hardware Behind Is Important |
| Presenter(s):William A. Gray, MD | |
| View Slides in PDF | |
| 10:19 AM - 10:24 AM | DEBATE: How Best To Manage Complex Femoropopliteal Lesions: A Vascular Surgeon’s Perspective |
| Presenter(s):Scott L. Stevens, MD | |
| View Slides in PDF | |
| 10:25 AM - 10:30 AM | DEBATE: How Best To Manage Complex Femoropopliteal Lesions: An Interventionalist’s Perspective |
| Presenter(s):Ulrich Beschorner, MD / Thomas Zeller, MD | |
| View Slides in PDF | |
| UPDATE ON DRUG COATED BALLOONS (DCBS | |
| 10:31 AM - 10:36 AM | Current Status, Limitations And Future Prospects For DCBs In Treatment Of Lower Extremity Ischemia: Are Their Benefits Sustained Mid- And Long-Term |
| Presenter(s):Gunnar Tepe, MD | |
| View Slides in PDF | |
| 10:37 AM - 10:42 AM | 3-Year Results Of The IN.PACT SFA Trial Comparing The In.Pact Admiral DCBs (Medtronic) With Standard Uncoated Balloons: Are The Benefits Of DCBs Over POBA Sustained |
| Presenter(s):John R. Laird, MD / Peter A. Schneider, MD | |
| View Slides in PDF | |
| 10:43 AM - 10:48 AM | Current Status, Value And Limitations Of DCBs In Fempop Occlusive Disease: Updates On The IN.PACT GLOBAL Registry And The LEVANT II Of The Lutonix DCB (Bard): Are The Benefits Over POBA Sustained |
| Presenter(s):Dierk Scheinert, MD / Marianne Brodmann, MD | |
| View Slides in PDF | |
| 10:49 AM - 10:54 AM | Importance Of Vessel Preparation With DCBs: Value Of Enforce Scoring Balloon (Cook) And Atherectomy With DCBs: Effect Of Calcium On DCBs Efficacy: Does The Lutonix DCB Work On BTK Arteries |
| Presenter(s):Plinio Rossi, MD / Fabrizio Fanelli, MD, EBIR | |
| View Slides in PDF | |
| 10:55 AM - 11:00 AM | Value Of The Legflow DCB vs. POBA For Long SFA Lesions: Proven By The RAPID RCT |
| Presenter(s):Jean-Paul de Vries, MD, PhD | |
| View Slides in PDF | |
| 11:01 AM - 11:06 AM | Panel Discussion |
| Moderator(s): Dierk Scheinert, MD / Gunnar Tepe, MD | |
| 11:06 AM - 11:11 AM | An Update On The ILLUMENATE Trial Series: What Makes The Stellarex DCB Different |
| Presenter(s):Sean P. Lyden, MD / Stefan Müller-Hülsbeck, MD / Marianne Brodmann, MD | |
| View Slides in PDF | |
| 11:12 AM - 11:17 AM | Early Results Of The DRASTICO RCT Comparing DESs And DEBs For The Treatment Of Fempop Lesions |
| Presenter(s):Francesco Liistro, MD | |
| View Slides in PDF | |
| 11:18 AM - 11:23 AM | What Is The Future Of DCBs In BTK And Crural Arteries: Why Some Of The RCTs Failed To Show A Benefit |
| Presenter(s):Krishna J. Rocha-Singh, MD | |
| View Slides in PDF | |
| 11:24 AM - 11:29 AM | Why DCBs Have Not Worked Well For BTK Lesions, But They Will - Recent RCTs Prove It (Like The Aco ART BTK Trial With The LITOS DCB): Different DCB Platforms Have Different Efficacy Especially BTK: What Is The Future Of DCBs In Crural Arteries |
| Presenter(s):Francesco Liistro, MD | |
| View Slides in PDF | |
| 11:30 AM - 11:35 AM | DEBATE: Status Of The BEST-CLI Multicenter/Multispecialty Trial Comparing Endovascular And Open Surgical Treatment Of CLI: It Will Be A Valuable Trial That Settles Controversy |
| Presenter(s):Matthew T. Menard, MD / Alik Farber, MD / Kenneth Rosenfield, MD | |
| View Slides in PDF | |
| 11:36 AM - 11:41 AM | DEBATE: Not So Fast: The BEST-CLI Trial May Not Be So Valuable And Here Is Why |
| Presenter(s):Mehdi H. Shishehbor, DO, MPH, PhD | |
| View Slides in PDF | |
| 11:42 AM - 11:47 AM | Status Of DCBs In The US: What Is Available; What Will Be Available And When |
| Presenter(s):Edward Y. Woo, MD | |
| View Slides in PDF | |
| 11:48 AM - 11:53 AM | How To Calculate Fractional Flow Reserve (FFR) And Collateral Reserve In The Periphery Without Pressure Wires And How Should This Information Be Used In Treatment Decisions |
| Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
| View Slides in PDF | |
| 11:54 AM - 12:00 PM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 26 | |
| SESSION 27 SCHEDULE | |
|
Wednesday
SESSION 27:
MORE ABOUT CLI; THE “NO-OPTION FOR TREATMENT” LIMB AND EXTREME LIMB SALVAGE TECHNIQUES AND RESULTS
Moderators:Sean P. Lyden, MD / Richard F. Neville, MD
|
|
| x | |
| 1:00 PM - 1:05 PM | Treatment Economics For CLI Care; Based On The SUPERSUB Trial |
| Presenter(s):Jihad A. Mustapha, MD | |
| View Slides in PDF | |
| 1:06 PM - 1:11 PM | Why There Is So Much Variation In The Definition Of A “No Option For Treatment Limb” In CLI: What Is A True Definition: Duplex Is The Best Way To Image Foot Arteries |
| Presenter(s):Hisham Rashid, FRCS, FRCS (Gen) | |
| View Slides in PDF | |
| 1:12 PM - 1:17 PM | Little Known Tips And Tricks For Visualizing And Treating Occluded Distal Leg And Foot Arteries With CLI And Gangrene: Contrast Angiography Is Best And How To Do It |
| Presenter(s):Roberto Ferraresi, MD | |
| View Slides in PDF | |
| 1:18 PM - 1:23 PM | Pedal Bypasses With Deep Vein Arterialization For Unfixable (No Option) Distal Arteries: Technique And Long-Term Results |
| Presenter(s):Pramook Mutirangura, FRCS (Edinburgh) | |
| View Slides in PDF | |
| 1:24 PM - 1:29 PM | Percutaneous Deep Vein Arterialization For End Stage CLI With Unfixable (No Option) Distal Arteries: Technique And Multicenter Results With The LimFlow Device |
| Presenter(s):Steven Kum, MD / Andrej Schmidt, MD / Daniel G. Clair, MD | |
| View Slides in PDF | |
| 1:30 PM - 1:35 PM | PTFE Grafts To Crural Arteries Are Procedures To Save Gangrenous Feet When No Other Option Is Available To Avoid A Major Amputation: Long-Term Patency Results Prove It Although Reoperations May Be Required |
| Presenter(s):Gregg S. Landis, MD / Neal S. Cayne, MD / Nicholas J. Gargiulo III, MD, RVT, RPVI, RDMS, FACS / Frank J. Veith, MD / Evan C. Lipsitz, MD | |
| View Slides in PDF | |
| 1:36 PM - 1:41 PM | In Patients With CLI And Necrotic Or Gangrenous Foot Lesions, Follow-Up After Interventional Treatment Is Crucial And Behavior Of The Wound Should Guide Re-Imaging And Reintervention |
| Presenter(s):Francesco Liistro, MD | |
| View Slides in PDF | |
| 1:42 PM - 1:47 PM | Tips And Tricks For Performing Distal Bypasses Successfully In Dialysis Patients |
| Presenter(s):Nobuyoshi Azuma, MD | |
| View Slides in PDF | |
| 1:48 PM - 1:53 PM | New Approaches To Limb Salvage In Advanced CLI Due To Very Distal Disease: Transcollateral, Pedal Loop And Small Artery Access In The Foot: How Durable Is The Patency Of PTAs Done By These Approaches |
| Presenter(s):Marco G. Manzi, MD | |
| View Slides in PDF | |
| 1:54 PM - 1:59 PM | Value Of Bypasses To Pedal Arteries For Advanced CLI After 10 Years Of Follow-Up: Technical Tips And When Should These Bypasses Be Performed |
| Presenter(s):Maarit Venermo, MD, PhD | |
| View Slides in PDF | |
| 2:00 PM - 2:06 PM | Panel Discussion |
| END OF SESSION 27 | |
| SESSION 28 SCHEDULE | |
|
Wednesday
SESSION 28:
NEW DEVELOPMENTS IN LOWER EXTREMITY DCBs, STENT-GRAFTS, PROSTHETIC GRAFTS AND THE TREATMENT OF IN-STENT RESTENOSIS (ISR)
Moderators:Johannes Lammer, MD / Joseph L. Mills, MD
|
|
| x | |
| 2:06 PM - 2:11 PM | How Important Are DCBs Currently: What Are Their Limitations: What Prospects And Advances Are In Their Future |
| Presenter(s):Giancarlo Biamino, MD, PhD | |
| View Slides in PDF | |
| 2:12 PM - 2:17 PM | Heparin Bonded PTFE (Propaten) Grafts Have 5-Year Patency Rates Equal To Autologous Vein Grafts For Fempop Bypasses |
| Presenter(s):Russell H. Samson, MD, RVT, FACS | |
| View Slides in PDF | |
| 2:18 PM - 2:23 PM | A RCT Comparng Endoluminal Bypass With Heparin Bonded PTFE Stent-Grafts (Viabahn) To Open Fempop Bypasses: 1-Year Results Of The SUPER B Trial |
| Presenter(s):Michel M.P. Reijnen, MD, PhD | |
| View Slides in PDF | |
| 2:24 PM - 2:29 PM | How To Achieve Good Results With Gore Viabahn Stent-Grafts For Complex Fempop Occlusive Disease: IVUS, Proper Sizing And Other Tips Are The Secrets To Success |
| Presenter(s):Hiroyoshi Yokoi, MD | |
| View Slides in PDF | |
| 2:30 PM - 2:35 PM | New Balloon Expandable Stent-Grafts (Viabahn Bx): Early Experience And How They Can Improve Performance |
| Presenter(s):Jean Bismuth, MD | |
| View Slides in PDF | |
| IN STENT RESTENOSIS (ISR) AND ITS TREATMENT | |
| 2:36 PM - 2:41 PM | Biology Of ISR And Rationale For Debulking Treatment: How Is ISR Best Treated At The Iliac And SFA Levels |
| Presenter(s):Jos C. van den Berg, MD, PhD | |
| View Slides in PDF | |
| 2:42 PM - 2:47 PM | What Are The Best Current Options For Treating ISR In The US: Role Of Atherectomy (With Laser And Other Devices), DCBs And Stent-Grafts |
| Presenter(s):Craig M. Walker, MD | |
| View Slides in PDF | |
| 2:48 PM - 2:53 PM | Role And Value Of Stent-Grafts In Treating ISR: Updated Results Of The RELINE Trial And Is Debulking Necessary |
| Presenter(s):Patrick Peeters, MD / Marc Bosiers, MD / Koen Deloose, MD | |
| View Slides in PDF | |
| 2:54 PM - 2:59 PM | Pitfalls In The Treatment Of ISR: What Is The Role Of The In.Pact Admiral DCB For SFA ISR: Is It Enough Alone |
| Presenter(s):Gary M. Ansel, MD | |
| View Slides in PDF | |
| 3:00 PM - 3:05 PM | Atherectomy Plus DCB Is The Best And Most Cost-Effective Treatment For SFA ISR: Based On The DEFINITIVE AR Trial: Tips And Tricks For Treating And Which Devices Are Best |
| Presenter(s):Gunnar Tepe, MD / Thomas Zeller, MD | |
| View Slides in PDF | |
| 3:06 PM - 3:12 PM | Panel Discussion |
| 3:12 PM - 3:22 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 28 | |
| SESSION 29 SCHEDULE | |
|
Wednesday
SESSION 29:
NEW DEVELOPMENTS IN THE TREATMENT OF ACUTE LIMB ISCHEMIA (ALI) AND INTERMITTENT CLAUDICATION (IC)
Moderators:Thomas O. McNamara, MD / Mark A. Adelman, MD
|
|
| x | |
| NEW METHODS TO TREAT ALI | |
| 3:22 PM - 3:27 PM | How To Perform A Femoral Embolectomy Without A Groin Incision: Technique And Advantages |
| Presenter(s):Rajiv Parakh, MBBS, MS, FRCS | |
| View Slides in PDF | |
| 3:28 PM - 3:33 PM | Update On Percutaneous Thrombosuction Techniques For ALI: Equipment, Methods And Results |
| Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
| View Slides in PDF | |
| 3:34 PM - 3:39 PM | Role Of Percutaneous Aspiration In ALI: What Are The Best Devices Available In The US And How Should They Be Used |
| Presenter(s):Michael H. Wholey, MD, MBA | |
| View Slides in PDF | |
| 3:40 PM - 3:45 PM | Advantages Of The Indigo Thrombectomy Device From Penumbra To Treat ALI: How Does It Get Clot Out More Effectively: Does It Have Disadvantages Or Limitations |
| Presenter(s):Patrick E. Muck, MD, FACS | |
| View Slides in PDF | |
| NEW CONCEPTS IN THE MANAGEMENT OF INTERMITTENT CLAUDICATION (IC) | |
| 3:46 PM - 3:51 PM | Use Of Electronic Devices To Improve Treatment Of Lower Extremity Intermittent Claudication: The Prospective FITBIT Study |
| Presenter(s):Robyn A. Macsata, MD | |
| View Slides in PDF | |
| 3:52 PM - 3:57 PM | A Wearable Exercise Tracker (NIKE + Fuel Band) Can Help To Improve Walking Distance In Intermittent Claudication: The wSTEP Trial |
| Presenter(s):Celia Riga, BSc, MBBS, MD, FRCS | |
| View Slides in PDF | |
| 3:58 PM - 4:03 PM | What Is The Best Non-Invasive Treatment To Improve Walking Distance In Patients With IC |
| Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh | |
| View Slides in PDF | |
| 4:04 PM - 4:09 PM | DEBATE: Angioplasty (PTA) Plus Exercise Is Better Treatment Than PTA Alone For IC: The ERASE Trial Shows It And Why It Is A Better Trial Than The CLEVER And MIMIC Trials |
| Presenter(s):Marc R.H.M. van Sambeek, MD, PhD | |
| View Slides in PDF | |
| 4:10 PM - 4:15 PM | DEBATE: Nonsense: Exercise, Best Medical Management And Reassurance Are The Best Treatment For Most Patients With IC |
| Presenter(s):Jonathan D. Beard, ChM, MEd, FRCS | |
| View Slides in PDF | |
| 4:16 PM - 4:22 PM | Panel Discussion |
| END OF SESSION 29 | |
| SESSION 30 SCHEDULE | |
|
Wednesday
SESSION 30:
VALUE OF DEEP VEIN GRAFTS; NEW CONCEPTS IN ASSESSING FOOT PERFUSION AND IMPROVING IT; MORE ABOUT THE ANGIOSOME CONTROVERSY; SOME ONGOING CLI TRIALS
Moderators:Kenneth Ouriel, MD, MBA / Timur P. Sarac, MD
|
|
| x | |
| 4:22 PM - 4:27 PM | A 40-Year Experience Using Femoropopliteal Veins For Below-Knee FP Bypasses: Describing The Positive Means And Dispelling The Negative Myths – You Can Do It |
| Presenter(s):Martin L. Schulman, MD | |
| View Slides in PDF | |
| 4:28 PM - 4:33 PM | A Novel Use Of Audio Technology To Evaluate Lower Extremity Perfusion And Eliminate Errors From Pulse Exams And Doppler Signals: The DZAM Technique |
| Presenter(s):Cynthia K. Shortell, MD / Leila Mureebe, MD | |
| View Slides in PDF | |
| 4:34 PM - 4:39 PM | Value Of A Computerized Rewarming Thermopneumatic Boot To Increase Blood Flow To Ischemic Lower Extremities: How It Works And Results |
| Presenter(s):Magdiel Trinidad Vasquez, MD | |
| View Slides in PDF | |
| 4:40 PM - 4:45 PM | Home Treatment For CLI: The Art Assist Sequential Compression Device: Principles And How It Works: Its Results Are Often Better Than A Bypass Or Interventional Treatment |
| Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC | |
| View Slides in PDF | |
| 4:46 PM - 4:50 PM | Panel Discussion |
| ANGIOSOME RELATED ISSUES AND TOPICS | |
| 4:50 PM - 4:55 PM | The Orphan Heel Syndrome: How To Identify It And What To Do About Necrotic Lesions In This Area |
| Presenter(s):Miguel F. Montero-Baker, MD | |
| View Slides in PDF | |
| 4:56 PM - 5:01 PM | Importance Of The Wound Related Artery (Angiosome) Concept And Patterns Of Disease In CLI: Should They Influence Treatment And How |
| Presenter(s):Roberto Ferraresi, MD | |
| View Slides in PDF | |
| 5:02 PM - 5:07 PM | Why Is There So Much Disagreement Over The Angiosome Concept And How To Resolve It: When Should A Pedal Bypass Be The First Option |
| Presenter(s):Hisham Rashid, FRCS, FRCS (Gen) | |
| View Slides in PDF | |
| 5:08 PM - 5:13 PM | DEBATE: New Evidence For The Value Of The Angiosome Concept In CLI With Tissue Loss: Indocyanide Green Injection With Fluorescence Imaging Shows It: The Angiosome Concept's Value Differs With Endo And Bypass Treatment |
| Presenter(s):Maarit Venermo, MD, PhD | |
| View Slides in PDF | |
| 5:14 PM - 5:19 PM | DEBATE: Despite All This, The Angiosome Concept Is Worthless And Here Is The Evidence |
| Presenter(s):Frank E.G. Vermassen, MD, PhD | |
| View Slides in PDF | |
| 5:20 PM - 5:25 PM | There Is Little Clinical Relevance To The Angiosome Concept: How Perfusion Can Be Measured In Parts Of The Foot So Healing Can Be Predicted |
| Presenter(s):Bauer E. Sumpio, MD, PhD | |
| View Slides in PDF | |
| 5:26 PM - 5:31 PM | When Is The Angiosome Concept Important And When Is It Not: How To Resolve The Controversy |
| Presenter(s):Ignacio Escotto, MD | |
| View Slides in PDF | |
| 5:32 PM - 5:37 PM | The Importance Of The Angiosome Concept And The Plantar Arch In CLI Patients With Extensive Foot Gangrene Or Ulceration: How To Evaluate Foot Perfusion And Potential For Healing |
| Presenter(s):Werner Lang, MD | |
| View Slides in PDF | |
| SOME ONGOING CLI TRIALS | |
| 5:38 PM - 5:43 PM | What Is The SPINACH Trial Comparing Endo And Open Treatment Of CLI: What Useful Information Will It Provide |
| Presenter(s):Nobuyoshi Azuma, MD | |
| View Slides in PDF | |
| 5:44 PM - 5:49 PM | What Is The LIBERTY Trial And What Unique Information Will It Provide About Advanced CLI And Its Endo And Open Treatments |
| Presenter(s):Jihad A. Mustapha, MD | |
| View Slides in PDF | |
| 5:50 PM - 5:58 PM | Panel Discussion End of Program D |
| END OF SESSION 30 | |
| SESSION 31 SCHEDULE | |
|
Wednesday
SESSION 31:
MONITORING HEPARIN; SCREENING FOR AND ASSESSING ATHEROSCLEROTIC RISK; ANTI- ATHEROSCLEROSIS TREATMENT CHANGES IN LIGHT OF NEW TRIAL FINDINGS; UPDATE ON TIMING OF SURGERY IN PATIENTS WITH CORONARY STENTS
Moderators:Gary M. Ansel, MD / Russell H. Samson, MD, RVT, FACS
|
|
| x | |
| 6:40 AM - 6:45 AM | Incidence And Importance Of Heparin Resistance In Vascular Procedures And How Measurement Of ACT Can Offset This Problem: Value Of Medtronic Hemostasis Management System |
| Presenter(s):Arno M. Wiersema, MD, PhD / Kak Khee Yeung, MD, PhD / Jan D. Blankensteijn, MD | |
| View Slides in PDF | |
| 6:46 AM - 6:51 AM | Pleiotropic Effect Of Statins: What Are They And How Should They Be Monitored |
| Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
| View Slides in PDF | |
| 6:52 AM - 6:57 AM | The Value Of Ultrasound Screening Of Femoral And Carotid Arteries To Predict Atherosclerotic Risk And What To Do About It |
| Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
| View Slides in PDF | |
| 6:58 AM - 7:03 AM | The VIVA RCT Is A Game Changer: It Shows That Population Based Screening For AAA, PAD And Hypertension Allows Intensive Medical Treatment With Statins And Anti-Hypertensives And That These Drugs Save Lives (7%) |
| Presenter(s):Jes S. Lindholt, MD | |
| View Slides in PDF | |
| 7:04 AM - 7:09 AM | Current Role Of PCSK 9 Inhibitors In LDL-Cholesterol (LDL-C) Management: How Do They Work And When Should They Be Given (Alirocumab-Praluent From Sanofi & Regeneron And Evolocumab-Repatha From Amgen) |
| Presenter(s):Ron Waksman, MD | |
| View Slides in PDF | |
| 7:10 AM - 7:15 AM | How To Manage Muscle Pain And Apparent Statin Intolerance In Patients On Statins: It Can Be Often Done Safely And Effectively Without Stopping Statins: What Does The GAUSS-3 Trial Tell Us About Controlling The Side Effects Of Statins |
| Presenter(s):Don Poldermans, MD | |
| View Slides in PDF | |
| 7:16 AM - 7:21 AM | Why LDL-C (Or Non-HDL-C) Levels Are Important Guides To Treatment And Should Be Followed In Primary And Secondary Event Prevention For Vascular Patients At Risk: Coronary Lesions Regress When LDL-C Is <80 mm/dL |
| Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Caron B. Rockman, MD | |
| View Slides in PDF | |
| 7:22 AM - 7:27 AM | Value Of Ezetimibe (Zetia) In Decreasing Death, Stroke And MI Rates When Added To Simvastatin: What Value Of LDL-C Should Our Patients Strive To Achieve: The IMPROVE-IT Trial: What Does The HOPE 3 Trial Tell Us About Crestor And Primary Prevention |
| Presenter(s):Ido Weinberg, MD, MSc | |
| View Slides in PDF | |
| 7:28 AM - 7:33 AM | New Key Findings From The JUPITER Trial: Statins (Crestor) Have Variability In Their LDL-C Lowering Ability; The Degree Of Cardiovascular Risk Reduction Correlates With The Percent LDL-C Reduction: Therapeutic Implications |
| Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Jonathan Newman, MD | |
| View Slides in PDF | |
| 7:34 AM - 7:39 AM | What Is New About Optimal Timing For Elective Vascular Surgery After Coronary Stenting For Angina; For MIs; With BMSs; With DESs: Things Have Changed: Risks Are Higher If The Stenting Was Done For An MI |
| Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
| View Slides in PDF | |
| 7:40 AM - 7:46 AM | Panel Discussion |
| END OF SESSION 31 | |
| SESSION 32 SCHEDULE | |
|
Wednesday
SESSION 32:
DRUG RESISTANT HYPERTENSION AND ITS CATHETER-BASED TREATMENTS; MEDICAL TREATMENTS; FRACTIONAL FLOW RESERVE; ASSESSMENT OF AAA RISK; UNUSUAL VASCULAR DISEASES
Moderators:Ron Waksman, MD / Anthony J. Comerota, MD, FACS, FACC
|
|
| x | |
| 7:46 AM - 7:51 AM | Why Pharmacological Treatments Are Insufficient To Control Hypertension In Some Patients And What Is The Outlook For Non-Pharmacologic Treatments; Renal Denervation And Baroreflex Stimulation (Neostim) And Modulation (Mobius) |
| Presenter(s):Melvin D. Lobo, MBChB , PhD, FRCP, FBHS, FESC | |
| View Slides in PDF | |
| 7:52 AM - 7:57 AM | What Is New With Endovascular Treatments Of Drug Resistant Hypertension: New Better Devices Like The Peregrine And Paradise Systems For Renal Denervation: New Study Results: Future Predictions |
| Presenter(s):Horst Sievert, MD | |
| View Slides in PDF | |
| 7:58 AM - 8:03 AM | Renal Artery Denervation For Hypertension: Why Hasn’t It Worked And Where Is It Going |
| Presenter(s):Krishna J. Rocha-Singh, MD | |
| View Slides in PDF | |
| 8:04 AM - 8:09 AM | Update On The ROX Endovascular System For Creating An Iliac A-V Fistula To Treat Resistant Hypertension: How It Works, Results And Complications |
| Presenter(s):David H. Deaton, MD, FACS | |
| View Slides in PDF | |
| 8:10 AM - 8:15 AM | Diagnostic Strategy For Children With Suspected Renin Mediated Hypertension Is Multimodal: Is Endovascular Treatment Ever Effective |
| Presenter(s):Kyung Cho, MD | |
| View Slides in PDF | |
| 8:16 AM - 8:21 AM | What’s New In The Pharmacologic Prevention And Treatment In Patients With Arteriosclerotic Vascular Disease – Where Are We Currently With Statins, PCSK 9 Inhibitors And Platelet Inhibitors |
| Presenter(s):Iris Baumgartner, MD | |
| View Slides in PDF | |
| 8:22 AM - 8:27 AM | Update On The Value Of Coronary CT And Fractional Flow Reserve (FFRct): Does It Eliminate Unnecessary Coronary Angiograms And Stents; Will The Technique Work In The Lower Extremity |
| Presenter(s):Christopher K. Zarins, MD | |
| View Slides in PDF | |
| 8:28 AM - 8:33 AM | How Skin Biopsy Can Predict AAA Growth Rates And Rupture |
| Presenter(s):Kak Khee Yeung, MD, PhD | |
| View Slides in PDF | |
| 8:34 AM - 8:39 AM | Systemic Inflammatory Disease: What Is It And How To Diagnose It: Does It Predict Increase Risk Of Post EVAR Complications, Type 2 Endoleak And Rupture |
| Presenter(s):Alan Dardik, MD, PhD | |
| View Slides in PDF | |
| 8:40 AM - 8:45 AM | Segmental Arterial Mediolysis: What Is It; What Is Its Clinical Significance; How To Diagnose And Treat It |
| Presenter(s):Samuel R. Money, MD, MBA | |
| View Slides in PDF | |
| 8:46 AM - 8:54 AM | Panel Discussion |
| END OF SESSION 32 | |
| SESSION 33 SCHEDULE | |
|
Wednesday
SESSION 33:
SIGNIFICANCE AND TREATMENT OF ENDOLEAKS AND AORTO-BRONCHIAL FISTULAS
Moderators:Juan C. Parodi, MD / Timur P. Sarac, MD
|
|
| x | |
| 8:54 AM - 8:59 AM | Embolization For Type 1A Endoleaks After Nellix And Standard Endografts: How To Do It And When Does It Work And When Does It Not |
| Presenter(s):Robert A. Morgan, MD | |
| View Slides in PDF | |
| 9:00 AM - 9:05 AM | How Does Onyx Work For Treating Type I Endoleaks: Limitations And Advantages |
| Presenter(s):Thomas Larzon, MD, PhD | |
| View Slides in PDF | |
| 9:06 AM - 9:11 AM | Value Of Duplex Ultrasound In Treating Endoleaks In The Presence Of Coils And Onyx And With Nellix Grafts |
| Presenter(s):Dipankar Mukherjee, MD | |
| View Slides in PDF | |
| 9:12 AM - 9:17 AM | Characterization System For Type 2 Endoleaks: What Is Its Clinical Significance |
| Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
| View Slides in PDF | |
| 9:18 AM - 9:23 AM | The Natural History Of Type 2 Endoleaks That Develop After 1 Year Is Different: >70% Persist And Require Closer Surveillance And More Interventions |
| Presenter(s):Keith D. Calligaro, MD / Matthew J. Dougherty, MD | |
| View Slides in PDF | |
| 9:24 AM - 9:29 AM | Catheter-Based CT Guided Translumbar Endoleak Treatment: Technique And Advantages |
| Presenter(s):Stephan Haulon, MD | |
| View Slides in PDF | |
| 9:30 AM - 9:35 AM | Accessory Renal Arteries – A Siginficant Source Of Bad Type 2 Endoleaks: How To Prevent, Diagnose And Treat Them |
| Presenter(s):Claudio J. Schonholz, MD / Joshua D. Adams, MD | |
| View Slides in PDF | |
| 9:36 AM - 9:41 AM | What Are The Causes Of Type 3 Endoleaks: Can Trauma Be One Of Them |
| Presenter(s):Carlo Setacci, MD | |
| View Slides in PDF | |
| 9:42 AM - 9:47 AM | AAA Wall Angiogenesis, A Previously Unrecognized Cause Of Endoleaks After EVAR: How To Diagnose And Treat Them |
| Presenter(s):Eric Allaire, MD, PhD | |
| View Slides in PDF | |
| 9:48 AM - 9:53 AM | Can Aorto-Bronchial Fistulas Be Managed Endovascularly: What Is The Hope Of Long-Term Survival |
| Presenter(s):Carlos E. Donayre, MD | |
| View Slides in PDF | |
| 9:54 AM - 10:02 AM | Panel Discussion |
| 10:02 AM - 10:16 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 33 | |
| SESSION 34 SCHEDULE | |
|
Wednesday
SESSION 34:
IMPORTANT ISSUES FOR VASCULAR SURGEONS AND SPECIALISTS; REMEMBRANCES; ASSET PROTECTION; KEY MEDICAL, HISTORICAL AND ETHICAL TOPICS
Moderators:Bruce A. Perler, MD, MBA / James C. Stanley, MD
|
|
| x | |
| 10:16 AM - 10:21 AM | Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly |
| Presenter(s):Jerry Goldstone, MD, FACS, FRCSEd | |
| View Slides in PDF | |
| 10:22 AM - 10:27 AM | Predictions For The Future In The Treatment Of Vascular Disease: Where Is Vascular Surgery Going |
| Presenter(s):Mark A. Adelman, MD | |
| View Slides in PDF | |
| 10:28 AM - 10:33 AM | Negotiating With Large Health Care Systems: Tips And Tricks For Individual Vascular Surgeons: How Could A Union Or Society Help |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Slides in PDF | |
| 10:34 AM - 10:39 AM | Beyond Vascular Surgery For Vascular Surgeons: Working With Industry: What Is Good About It And What Is Bad |
| Presenter(s):David H. Deaton, MD, FACS | |
| View Slides in PDF | |
| 10:40 AM - 10:45 AM | Why Vascular Surgeons Are An Essential Operating Room Resource For Other Surgeons: They Must Be Valued As Such, Protected And Compensated |
| Presenter(s):Gregory L. Moneta, MD | |
| View Slides in PDF | |
| 10:46 AM - 10:51 AM | Is It A Wild West Bonanza Or A Feeding Frenzy: How To Stem The Surge In Unnecessary Lower Extremity Interventions That Cost So Much And Do Little To Benefit Patients |
| Presenter(s):Scott L. Stevens, MD | |
| View Slides in PDF | |
| 10:52 AM - 10:57 AM | Key Points In Asset Protection, Tax Planning And Succession Planning For Vascular Surgeons/Specialists |
| Presenter(s):Hillel Presser, Esq., MBA | |
| View Slides in PDF | |
| 10:58 AM - 11:04 AM | Panel Discussion |
| KEY NON-SURGICAL ISSUES | |
| Moderator(s): Michael L. Marin, MD / Frank J. Veith, MD | |
| 11:04 AM - 11:09 AM | Optimal Treatment For Left Main Coronary Lesion Is Changing: Stenting With DESs Is Replacing Open Coronary Bypass: Based On The EXCEL Trial |
| Presenter(s):Gregg W. Stone, MD | |
| View Slides in PDF | |
| 11:10 AM - 11:15 AM | COURAGE Trial Findings After 15 Years Follow-Up: It Still Shows No Advantage Over Medical Treatment In Some Coronary Disease Patients: Are Too Many Patients Getting Coronary Stents |
| Presenter(s):Roxana Mehran, MD | |
| View Slides in PDF | |
| 11:16 AM - 11:21 AM | Role Of Stents In The Treatment Of Lower Extremity Occlusive Lesions: Value Of DESs And DCBs: Will Bare Metal Stent Usage Decrease Or Disappear |
| Presenter(s):John H. Rundback, MD, FSIR, FAHA | |
| View Slides in PDF | |
| 11:22 AM - 11:27 AM | Current Status Of Cell And Gene Therapy For CLI Treatment: Do Either Have A Future |
| Presenter(s):Sigrid Nikol, MD | |
| View Slides in PDF | |
| 11:28 AM - 11:33 AM | Long-Term Results Of Autologous Bone Marrow Cell Treatment For No Option CLI: Results Of A Double Blinded RCT |
| Presenter(s):Thomas F. O'Donnell, Jr., MD / Mark D. Iafrati, MD | |
| View Slides in PDF | |
| AN HISTORICAL NOTE | |
| 11:34 AM - 11:39 AM | What Are “Octopus” Endografts: Why Are They The Future Of Branched Endografting For TAAAs And What Is Their Origin |
| Presenter(s):Karthikeshwar Kasirajan, MD | |
| View Slides in PDF | |
| ETHICAL ISSUES | |
| 11:40 AM - 11:45 AM | Ethical Conflicts In Providing Quality Care With All The Financial And RVU Pressures In The Current Health Care System: How To Resolve Them |
| Presenter(s):James W. Jones, MD, PhD, MHA | |
| View Slides in PDF | |
| 11:46 AM - 11:51 AM | How To Involve Vascular Patients In Decision Making About Their Surgical And Interventional Treatments |
| Presenter(s):Dirk T. Ubbink, MD, PhD | |
| View Slides in PDF | |
| 11:52 AM - 12:00 PM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 34 | |
| SESSION 35 SCHEDULE | |
|
Wednesday
SESSION 35:
THE CURRENT HEALTH CARE SYSTEM; REIMBURSEMENT; IMPACT OF OBAMACARE (ACA), ACOs, ETC. ON VASCULAR SURGEONS/SPECIALISTS AND OUR INDUSTRY PARTNERS
Moderators:Michel Makaroun, MD / John H. Furtek, BS, RT(r)
|
|
| x | |
| 1:00 PM - 1:05 PM | Effects Of The Massachusetts Universal Health Care Program On Vascular Surgery And Its Outcomes: Is It A Model For What Will Happen Under Obama Care Or The Affordable Care Act (ACA) |
| Presenter(s):Mohammad H. Eslami, MD, MPH | |
| View Slides in PDF | |
| 1:06 PM - 1:11 PM | Obamacare 2016: Is It As Bad As Predicted Or Worse: Can It Be Fixed |
| Presenter(s):Clifford J. Buckley, MD | |
| View Slides in PDF | |
| 1:12 PM - 1:17 PM | Is The ACA (Obamacare) Increasing Or Decreasing Access To Affordable Care |
| Presenter(s):Bruce A. Perler, MD, MBA | |
| View Slides in PDF | |
| 1:18 PM - 1:23 PM | Impact Of The ACA On Vascular Surgery’s Value To The Health Care System: It’s Not Good |
| Presenter(s):Richard J. Powell, MD | |
| View Slides in PDF | |
| 1:24 PM - 1:29 PM | Impact Of The Medical Device Tax On Medical Innovation And Education: Will It Be Repealed Or Just Delayed: Other Effects Of The ACA On The Medical Device Industry And Its Support Of Continuing Medical Education |
| Presenter(s):Allison H. Giles, RN, JD | |
| View Slides in PDF | |
| 1:30 PM - 1:35 PM | Alternate Payment Models And ACOs (Accountable Care Organizations): How Are They Working, Will They Work And What Will Their Impact Be On Vascular Surgeons |
| Presenter(s):Robert M. Zwolak, MD, PhD | |
| View Slides in PDF | |
| 1:36 PM - 1:41 PM | Impact Of The Medicare Access And CHIP Reauthorization Act Of 2015 (MACRA) On US Vascular Surgeons: Why It Is A Big Problem |
| Presenter(s):Timothy F. Kresowik, MD | |
| View Slides in PDF | |
| 1:42 PM - 1:47 PM | What Is Happening With Reimbursement For Vascular Surgeons: What Does The Future Hold |
| Presenter(s):Sean P. Roddy, MD | |
| View Slides in PDF | |
| 1:48 PM - 1:53 PM | How To Survive In A Hostile Health Care Environment: Systematizing Vascular Doctor/Hospital Alignment And Making The Hospital Vascular Services More Profitable Without Doing Unnecessary Procedures |
| Presenter(s):Barry T. Katzen, MD | |
| View Slides in PDF | |
| 1:54 PM - 1:59 PM | Starting A Vascular Surgery Service In A Public Safety Net Hospital Can Be Profitable: Tips And Strategies For Success During Insurance And Health Care Reform |
| Presenter(s):Charles J. Fox, MD, FACS | |
| View Slides in PDF | |
| 2:00 PM - 2:06 PM | Panel Discussion |
| END OF SESSION 35 | |
| SESSION 36 SCHEDULE | |
|
Wednesday
SESSION 36:
GOVERNING BODIES (BOARDS/RRC); INDEPENDENCE; MOC; MENTORSHIP; COMPETENCE; TRAINING/SIMULATION
Moderators:Carlo A. Dall'Olmo, MD / William D. Jordan Jr., MD
|
|
| x | |
| 2:06 PM - 2:11 PM | History Of The American Board of Vascular Surgery (ABVS) – Where Does Vascular Surgery Stand – What Is Missing |
| Presenter(s):James C. Stanley, MD | |
| View Slides in PDF | |
| 2:12 PM - 2:17 PM | Advantages To A Division Of Vascular Surgery When It Is Part Of A Department Of General Surgery |
| Presenter(s):H. Leon Pachter, MD | |
| View Slides in PDF | |
| 2:18 PM - 2:23 PM | Why Vascular Surgery Needs To Be A Totally Independent Specialty And How Can We Get There |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Slides in PDF | |
| 2:24 PM - 2:29 PM | MOC (Maintenance Of Certification): Is It Valuable, In Need Of Modification Or A Waste Of Time And Money: Does Vascular Surgery Need More Independence With Its Own Board And RRC |
| Presenter(s):John F. Eidt, MD | |
| View Slides in PDF | |
| 2:30 PM - 2:35 PM | Who Should Be Doing The Complex Open Vascular Surgery (Pararenal AAAs, TAAAs, Mesenteric And Tibial Bypasses): Trainee Experience Is Limited: Do We Need Regional Centers And What Are The Downsides |
| Presenter(s):Ronald L. Dalman, MD | |
| View Slides in PDF | |
| 2:36 PM - 2:41 PM | Major Open Surgery Experience Differences Between 5+2 And 0+5 Vascular Trainees: Does It Matter |
| Presenter(s):Murray L. Shames, MD | |
| View Slides in PDF | |
| 2:42 PM - 2:48 PM | Panel Discussion |
| Moderator(s): Karl A. Illig, MD / Ronald L. Dalman, MD | |
| 2:48 PM - 2:53 PM | Role And Progress Of Women In Vascular Surgery: Value Of Mentorship And How To Promote It |
| Presenter(s):Robyn A. Macsata, MD | |
| View Slides in PDF | |
| VASCULAR AND SURGICAL SIMULATORS | |
| 2:54 PM - 2:59 PM | Should All Surgeons Have To Work On Simulators – Like Pilots |
| Presenter(s):O. William Brown, MD, JD | |
| View Slides in PDF | |
| 3:00 PM - 3:05 PM | How To Shift Learning Curves From Patients To Models (Simulators) And How To Assess Technical Skills With Models |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Slides in PDF | |
| 3:06 PM - 3:11 PM | Proficiency Based Stepwise Endovascular Training Improves Performance In The Hybrid Suite: A RCT (The PROSPECT Trial) Proves It |
| Presenter(s):Isabelle van Herzeele, MD, PhD / Heidi Maertens, PhD | |
| View Slides in PDF | |
| 3:12 PM - 3:17 PM | How To Determine Proficiency In EVAR And Radiation Safety: Does Simulator Training Help |
| Presenter(s):Lars B. Lonn, MD, PhD / Torben V. Schroeder, MD, DMSc | |
| View Slides in PDF | |
| 3:18 PM - 3:23 PM | How To Train Practicing Vascular Surgeons/Specialists For New Procedures; “Gloves On Training” Can Do It: What Are The Essential Elements |
| Presenter(s):Jon S. Matsumura, MD | |
| View Slides in PDF | |
| 3:24 PM - 3:30 PM | Panel Discussion |
| 3:30 PM - 3:40 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 36 | |
| SESSION 37 SCHEDULE | |
|
Wednesday
SESSION 37:
NEW DEVELOPMENTS IN VASCULAR CARE, DRGs, TELEMEDICINE, REIMBURSEMENTS, REPORTING BAD PRACTICE AND THE FDA
Moderators:Bruce A. Perler, MD, MBA / Ronald M. Fairman, MD
|
|
| x | |
| 3:40 PM - 3:45 PM | How Does A Real-Time Dashboard Database Improve The Quality And Decrease The Cost Of Vascular Care |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Slides in PDF | |
| 3:46 PM - 3:51 PM | How Can Hospitalists Improve A Vascular Service By Decreasing Mortality, Length Of Stay And Readmissions |
| Presenter(s):Peter L. Faries, MD, FACS | |
| View Slides in PDF | |
| 3:52 PM - 3:57 PM | Volume/Outcome Relationship With CEA And CAS: German Registry Data From 175,000 Patients |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Slides in PDF | |
| 3:58 PM - 4:03 PM | Hospital Volume Matters Most In Improving Outcome Of EVAR: Both Surgeon And Hospital Volume Matter For Open AAA Repair |
| Presenter(s):Marc L. Schermerhorn, MD | |
| View Slides in PDF | |
| 4:04 PM - 4:09 PM | How To Incorporate Virtual Visits Into A Vascular Practice: The Technology Is Here: What Is The Technology And How To Use It |
| Presenter(s):John (Jeb) W. Hallett, MD | |
| View Slides in PDF | |
| 4:10 PM - 4:15 PM | Role Of Telemedicine In A Vascular Practice: How To Be Reimbursed For It |
| Presenter(s):Clifford M. Sales, MD, MBA, FACS | |
| View Slides in PDF | |
| 4:16 PM - 4:21 PM | Benefit Of New AAA/EVAR DRGs On Hospital Economics: They Are A Game Changer And How They Can Benefit Vascular Surgeons |
| Presenter(s):W. Charles Sternbergh III, MD | |
| View Slides in PDF | |
| 4:22 PM - 4:27 PM | We Have A Duty To Report Unethical Procedures Or Malpractice To Hospital Administrators, State Misconduct Boards And Patients Seeking A Second Opinion: Why It Does Not Happen And What To Do If Such Reporting Does No Good Because Of Administrator Inaction |
| Presenter(s):O. William Brown, MD, JD | |
| View Slides in PDF | |
| 4:28 PM - 4:33 PM | Ezetimbe (Zetia) Lowers LDL-C And Decreases Cardiovascular Death, MI And Stroke Over Statins Alone: When Should It Be Given And Why Didn’t The FDA Approve It |
| Presenter(s):Russell H. Samson, MD, RVT, FACS | |
| View Slides in PDF | |
| 4:34 PM - 4:39 PM | Why Does The FDA Approve Lower Extremity Devices With Only 6-12 Months Follow-Up: Shouldn’t Longer Durability Be Required |
| Presenter(s):Dorothy B. Abel, BSBME | |
| View Slides in PDF | |
| 4:40 PM - 4:46 PM | Panel Discussion |
| END OF SESSION 37 | |
| SESSION 38 SCHEDULE | |
|
Wednesday
SESSION 38:
TRIALS/REGISTRIES; FLAWS IN REPORTING AND RCTs; PUBLICATION QUALITY; SVS STANDARDS AND GUIDELINES; FAIR DEVICE EVALUATION; VALUE OF VQIs
Moderators:Michael S. Conte, MD / Keith D. Calligaro, MD
|
|
| x | |
| TRIALS, REGISTRIES AND REPORTING | |
| 4:46 PM - 4:51 PM | Registries vs. Trials: Pros And Cons Of Each: What Should Guide Clinical Practice |
| Presenter(s):Vicente Riambau, MD, PhD | |
| View Slides in PDF | |
| 4:52 PM - 4:57 PM | Why Kaplan-Meier Analyses Are A Poor Way To Compare Devices And Treatments For PAD: How Should It Be Done |
| Presenter(s):Frank E.G. Vermassen, MD, PhD | |
| View Slides in PDF | |
| 4:58 PM - 5:03 PM | Surgeon Outcome Reporting Can Be Inaccurate And Unreliable: What Is The Evidence |
| Presenter(s):Mr. Jonathan R. Boyle, MD, FRCS | |
| View Slides in PDF | |
| 5:04 PM - 5:09 PM | Critical Analysis Of Clinical Trials And Randomized Controlled Trials (RCTs): They Have Value But Many Pitfalls |
| Presenter(s):Anton N. Sidawy, MD, MPH | |
| View Slides in PDF | |
| 5:10 PM - 5:15 PM | RCTs Are Often Poorly Generalizable: What Strategies Can Overcome This Flaw |
| Presenter(s):Charles C. Miller, PhD | |
| View Slides in PDF | |
| 5:16 PM - 5:21 PM | With Published Articles In The Medical Literature Quality Should Trump Quantity: Does It And How Should Quality Be Evaluated |
| Presenter(s):Clifford J. Buckley, MD | |
| View Slides in PDF | |
| 5:22 PM - 5:28 PM | Panel Discussion |
| REPORTING STANDARDS, GUIDELINES, VQIS | |
| Moderator(s): Anton N. Sidawy, MD, MPH / Peter Gloviczki, MD | |
| 5:28 PM - 5:33 PM | Important Changes And Aspects Of The New SVS Reporting Standards |
| Presenter(s):Michael C. Stoner, MD | |
| View Slides in PDF | |
| 5:34 PM - 5:39 PM | Highlights Of The New SVS Guidelines For Management Of The Diabetic Foot: Value Of Total Contact Cast For Diabetic Ulcers |
| Presenter(s):Anil P. Hingorani, MD | |
| View Slides in PDF | |
| 5:40 PM - 5:45 PM | How To And How Not To Measure Quality: The Current System Has It Wrong |
| Presenter(s):Clifford M. Sales, MD, MBA, FACS | |
| View Slides in PDF | |
| 5:46 PM - 5:51 PM | Two New Initiatives To Measure The Value Of Endovascular Devices Over Medical Treatment For Lower Extremity Occlusive Lesions: The Multidisciplinary RAPID Project And The VQI Registry Of Medical Treatment: How Do They Work |
| Presenter(s):Jack L. Cronenwett, MD | |
| View Slides in PDF | |
| 5:52 PM - 5:57 PM | How Well Do VQI And Non-VQI Hospitals Perform In Quality Measures: Do Quality Measures Reflect Quality And Really Matter |
| Presenter(s):Philip P. Goodney, MD, MS | |
| View Slides in PDF | |
| 5:58 PM - 6:05 PM | Panel Discussion End of Program E |
| END OF SESSION 38 | |
| SESSION 39 SCHEDULE | |
|
Wednesday
SESSION 39:
MORE TOPICS RELATED TO TEVAR, THE THORACIC AORTA AND TREATMENT OF AORTIC DISSECTIONS
Moderators:Roberto Chiesa, MD / ShenMing Wang, MD, PhD
|
|
| x | |
| 6:54 AM - 6:59 AM | Aortic Dissection Chronicity Is Patient Specific Not Time Determined: Need IVUS Or 4D MRI To Determine Flap Mobility And Plan Treatment |
| Presenter(s):Ross Milner, MD | |
| View Slides in PDF | |
| 7:00 AM - 7:05 AM | Update On The True Lumen/False Lumen Ratio As A Predictor Of Need For TEVAR Treatment With TBAD Patients |
| Presenter(s):Jean M. Panneton, MD | |
| View Slides in PDF | |
| 7:06 AM - 7:11 AM | Strategies And Solutions When TEVAR Fails In Treating A TBAD |
| Presenter(s):Joseph V. Lombardi, MD | |
| View Slides in PDF | |
| 7:12 AM - 7:19 AM | Experience With Carotid Subclavian Bypass To Revascularize The LSA With TEVAR: Technique, Complications And Outcomes |
| Presenter(s):Sebastian E. Debus, MD, PhD | |
| View Slides in PDF | |
| 7:18 AM - 7:23 AM | Although 30-Day Mortality For TEVAR For Elective And Ruptured Thoracic Aneurysms, And TBAD Is Good, Longer Term Survival Is Poor – Especially For Ruptures |
| Presenter(s):Anders Wanhainen, MD, PhD | |
| View Slides in PDF | |
| 7:24 AM - 7:29 AM | What Are The Expansion Rates Of Thoracic Aortic Aneurysms At Various Levels And At What Diameter Should They Be Fixed Because Of Increased Rupture Risk |
| Presenter(s):John A. Elefteriades, MD | |
| View Slides in PDF | |
| 7:30 AM - 7:35 AM | Influence Of Arterial Hypertension Or Hypotension On Aortic Diameter And How Should Blood Pressure Influence Diameter Sizing Of Endografts For TEVAR |
| Presenter(s):Frank J. Criado, MD, FACS, FSVM | |
| View Slides in PDF | |
| 7:36 AM - 7:41 AM | What Does Volume Analysis Of True And False Lumens Tell Us After Standard And Petticoat (Composite) TEVAR For Acute TBADs |
| Presenter(s):Stephan Haulon, MD | |
| View Slides in PDF | |
| 7:42 AM - 7:47 AM | 5-Year Outcomes (Durability) Of TEVAR: For Thoracic Aortic Aneurysms: Data From The VALOR II Registry |
| Presenter(s):Mark Conrad, MD, MMSc / Richard P. Cambria, MD | |
| View Slides in PDF | |
| 7:48 AM - 7:53 AM | 30 Years Of Chinese Progress In Treating TBADs: What Has Happened In The Last 5 Years And What Challenges Remain |
| Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
| View Slides in PDF | |
| 7:54 AM - 8:00 AM | Panel Discussion |
| END OF SESSION 39 | |
| SESSION 40 SCHEDULE | |
|
Wednesday
SESSION 40:
TREATMENT OF LESIONS OF THE ASCENDING AORTA, THE AORTIC ARCH; PARALLEL GRAFTS AND OTHER METHODS AND DEVICES FOR TREATMENT
Moderators:Eric E. Roselli, MD / Roberto Chiesa, MD
|
|
| x | |
| 8:00 AM - 8:05 AM | Endovascular Repair Of Ascending Aortic Lesions: Where Does It Stand |
| Presenter(s):Ali Azizzadeh, MD | |
| View Slides in PDF | |
| 8:06 AM - 8:11 AM | Advantages, Limitations And Long-Term Results Of Chimney And Periscope Grafts For Aortic Arch Lesions |
| Presenter(s):Nicola Mangialardi, MD / Mario L. Lachat, MD | |
| View Slides in PDF | |
| 8:12 AM - 8:17 AM | For Aortic Arch Aneurysms; Parallel Grafts vs. Open Surgical Debranching: When, Where And How |
| Presenter(s):Franco Grego, MD | |
| View Slides in PDF | |
| 8:18 AM - 8:23 AM | Chimney Grafts Are Better Than Other Techniques For Aortic Arch Lesions – And Are Simpler And Cheaper: How To Make Them Safe And Effective: Limitations |
| Presenter(s):Jan S. Brunkwall, MD, PhD | |
| View Slides in PDF | |
| 8:24 AM - 8:29 AM | Advantages, Limitations And Failure Modes Of Chimney Grafts For Aortic Arch Lesions: How To Prevent Failures |
| Presenter(s):Ralf R. Kolvenbach, MD | |
| View Slides in PDF | |
| 8:30 AM - 8:35 AM | A Novel (Nexus) Endograft When Parallel Grafts Won’t Work In The Arch – Concept, Technique And Early Results |
| Presenter(s):Mario L. Lachat, MD / Nicola Mangialardi, MD | |
| View Slides in PDF | |
| 8:36 AM - 8:41 AM | Further Experience With Total Endovascular Repair Of Aortic Arch Lesions Using A Precurved Fenestrated Endograft (Naguta): Indications, Advantages, Results And Limitations |
| Presenter(s):Yoshihiko Yokoi, MD | |
| View Slides in PDF | |
| 8:42 AM - 8:47 AM | Branched Endograft vs. Chimneys For Treating Complex Arch Lesions: Advantages, Results And Limitations Of Each |
| Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
| View Slides in PDF | |
| 8:48 AM - 8:53 AM | Open And Endo Options For Treating Kommerell’s Diverticula And Other Congenital Arch Lesions |
| Presenter(s):Nicholas J.W. Cheshire, MD | |
| View Slides in PDF | |
| 8:54 AM - 9:00 AM | Panel Discussion |
| 9:00 AM - 9:18 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 40 | |
| SESSION 41 SCHEDULE | |
|
Wednesday
SESSION 41:
MORE ABOUT JUXTA- AND PARARENAL AAAs; TAAAs; F/BEVAR; PARALLEL GRAFTS
Moderators:Timothy A.M. Chuter, DM / Eric L.G. Verhoeven, MD, PhD
|
|
| x | |
| 9:18 AM - 9:23 AM | Natural History Of TAAAs: How Should It Influence Treatment |
| Presenter(s):Anthony L. Estrera, MD / Hazim J. Safi, MD | |
| View Slides in PDF | |
| 9:24 AM - 9:29 AM | Endovascular Treatment Of TAAAs: The Chinese Experience: What Is The Best Graft |
| Presenter(s):Wei Guo, MD | |
| View Slides in PDF | |
| 9:30 AM - 9:35 AM | How Renal Artery Angulation And Respiratory Motion Affect The Long- Term Results Of Chimney EVAR (Ch/EVAR) And Fenestrated EVAR (F/EVAR) |
| Presenter(s):Ronald L. Dalman, MD | |
| View Slides in PDF | |
| 9:36 AM - 9:41 AM | Comparative Results Of F/EVAR And Ch/EVAR For Juxtarenal AAAs: Which Is Best And When |
| Presenter(s):Murray L. Shames, MD | |
| View Slides in PDF | |
| 9:42 AM - 9:47 AM | In Vitro Studies Allow Optimization Of Chimney Graft Details (Measurements, Types Of Graft, Overlap Length And Need For Endoanchors) With Standard, Nellix And Ovation Endografts: Gutter Endoleaks Can Be Prevented |
| Presenter(s):Kak Khee Yeung, MD, PhD / Jan D. Blankensteijn, MD / Willem Wisselink, MD | |
| View Slides in PDF | |
| 9:48 AM - 9:53 AM | Failure Modes After Branched EVAR (B/EVAR) For TAAAs And How They Can Be Prevented |
| Presenter(s):Matthew J. Eagleton, MD / Tara M. Mastracci, MD | |
| View Slides in PDF | |
| 9:54 AM - 9:59 AM | Tips And Tricks For And Results Of Open TAAA Repair After Failed TEVAR Or EVAR |
| Presenter(s):Roberto Chiesa, MD / Germano Melissano, MD | |
| View Slides in PDF | |
| 10:00 AM - 10:06 AM | Panel Discussion |
| Moderator(s): Matthew J. Eagleton, MD / Marcelo Ferreira, MD | |
| 10:06 AM - 10:11 AM | What Are The Ideal Bridging Stent-Grafts For Use With F/EVAR And B/EVAR |
| Presenter(s):Daniel G. Clair, MD | |
| View Slides in PDF | |
| 10:12 AM - 10:17 AM | Target Branch Vessel Injuries In F/EVAR And B/EVAR: How To Prevent And Treat Them |
| Presenter(s):W. Anthony Lee, MD | |
| View Slides in PDF | |
| 10:18 AM - 10:23 AM | How To Predict Rotation And Torsion Of Fenestrated Endografts So These Problems Can Be Eliminated |
| Presenter(s):Thomas L. Forbes, MD | |
| View Slides in PDF | |
| 10:24 AM - 10:29 AM | Technical Tips For Making Standard F/EVAR And F/EVAR After Failed EVAR: Simpler, Safer And Better |
| Presenter(s):Timothy A. Resch, MD, PhD | |
| View Slides in PDF | |
| 10:30 AM - 10:35 AM | How To Modify A Gore C3 Excluder For A 3 Branch F/EVAR: Results And Technique (Video Presentation) |
| Presenter(s):Wayne W. Zhang, MD | |
| View Slides in PDF | |
| 10:36 AM - 10:41 AM | How To Obtain Adequate Reimbursement For F/EVAR Procedures In The US |
| Presenter(s):Francesco A. Aiello, MD | |
| View Slides in PDF | |
| 10:42 AM - 10:47 AM | A New Device To Simplify F/BEVAR: A Guidewire Fixator: How It Works, Advantages And Limitations |
| Presenter(s):Krister C.B. Liungman, PhD | |
| View Slides in PDF | |
| 10:48 AM - 10:54 AM | Panel Discussion |
| END OF SESSION 41 | |
| SESSION 42 SCHEDULE | |
|
Wednesday
SESSION 42:
UPDATE ON THE MULTILAYER FLOW MODULATING (MLFM) STENTS AND OTHER UNCOVERED STENTS FOR THE TREATMENT OF ANEURYSMS AND DISSECTIONS
Moderators:Rodney A. White, MD / Frans L. Moll, MD, PhD
|
|
| x | |
| 10:54 AM - 10:59 AM | Value Of Flow Diverting Bare Stents In Treating Aneurysms: When Do They Work And When Don’t They: What Is The Theory And The Evidence |
| Presenter(s):Maria Antonella Ruffino, MD, EBIR / Fabrizio Fanelli, MD, EBIR | |
| View Slides in PDF | |
| 11:00 AM - 11:05 AM | Flow Diverting Bare Stents With Or Without Coils For Treating Visceral Or Renal Artery Aneurysms: How Well Do They Work And Could Similar Stents Work For Aortic Aneurysms |
| Presenter(s):Wassim Mansour, MD / Michele Rossi, MD | |
| View Slides in PDF | |
| 11:06 AM - 11:11 AM | Early Results With MLFM Uncovered Stents To Treat Acute Aortic Dissections: The DRAGON Trial: What About Their Use In Treating Aortic Aneurysms |
| Presenter(s):Ralf R. Kolvenbach, MD | |
| View Slides in PDF | |
| 11:12 AM - 11:17 AM | Updated Experience Treating Aortic Dissections And Complex AAAs With MLFM Uncovered Stents |
| Presenter(s):Victor S. Costache, MD, PhD | |
| View Slides in PDF | |
| 11:18 AM - 11:23 AM | Results Of MLFM Stents For Treating Aortic Dissections: When Are They The Best Treatment: What About For Complex Aortic Aneurysms (TAAAs) |
| Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC | |
| View Slides in PDF | |
| 11:24 AM - 11:29 AM | 5-Year Results Of The French Registry Of MLFM Stent Treatment Of Complex Aortic Aneurysms: What Is Good, What Is Not And What Remains Unknown |
| Presenter(s):Rodney A. White, MD / Claude D. Vaislic, MD | |
| View Slides in PDF | |
| 11:30 AM - 11:35 AM | The Japanese Clinical Experience With The MLFM Stent For The Treatment Of Aortic Aneurysms And Dissections |
| Presenter(s):Yoshikatsu Saiki, MD, PhD | |
| View Slides in PDF | |
| 11:36 AM - 11:41 AM | Update On The Experience With Multilayered Uncovered Stents In Treating TAAAs: Value And Limitations |
| Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
| View Slides in PDF | |
| 11:42 AM - 11:47 AM | Theoretical Considerations In Using MLFM Uncovered Stents (From Cardiatis) To Treat Aortic Dissections |
| Presenter(s):Lambros Athanasiou, PhD / Elazer R. Edelman, MD, PhD | |
| View Slides in PDF | |
| 11:48 AM - 11:53 AM | Another Observer’s Opinion On The Value Of Uncovered Flow Modulating Stents In The Treatment Of Aneurysms And Dissections |
| Presenter(s):Manish Mehta, MD, MPH / Michael D. Dake, MD | |
| View Slides in PDF | |
| 11:54 AM - 12:00 PM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade And Rhinelander Gallery Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 42 | |
| SESSION 43 SCHEDULE | |
|
Wednesday
SESSION 43:
MORE INTERESTING TOPICS RELATED TO THE ABDOMINAL AORTA, AAAs AND EVAR
Moderators:Roger M. Greenhalgh, MD / Timur P. Sarac, MD
|
|
| x | |
| 1:00 PM - 1:05 PM | Value Of Simulation With EVAR: Does It Improve Seal Zone Coverage: Other Advantages |
| Presenter(s):Vikram S. Kashyap, MD | |
| View Slides in PDF | |
| 1:06 PM - 1:11 PM | How To Do EVAR Safely With Almost No Contrast In Patients With Chronic Renal Disease: Is It Of Value |
| Presenter(s):Andrea Stella, MD | |
| View Slides in PDF | |
| 1:12 PM - 1:17 PM | Aortic Neck Enlargement Differs After EVAR With Balloon-Expandable And Self-Expandable Endografts: Why Does It Matter |
| Presenter(s):Dainis K. Krievins, MD | |
| View Slides in PDF | |
| 1:18 PM - 1:23 PM | DEBATE: Large Diameter Aortic Necks (>32 mm) Are Associated With More Type 1A Endoleaks, Migration And Other Problems And Should Be A Relative Contraindication To EVAR |
| Presenter(s):Ali F. AbuRahma, MD | |
| View Slides in PDF | |
| 1:24 PM - 1:29 PM | DEBATE: Large Diameter Aortic Necks (35-36 mm) Are Not Associated With More Type 1A Endoleaks, Migration, Etc.: What Techniques Can Help |
| Presenter(s):Michael J. Singh, MD | |
| View Slides in PDF | |
| 1:30 PM - 1:35 PM | Nellix Endografts And EVAS Can Be Effective In Treating AAAs With Large Common Iliac Aneurysms: Technique And Results: From A Multicenter Experience |
| Presenter(s):Jean-Paul de Vries, MD, PhD | |
| View Slides in PDF | |
| 1:36 PM - 1:41 PM | DEBATE: The Case For Lowering The Threshold For AAA Treatment In Many Patients |
| Presenter(s):Ronald M. Fairman, MD | |
| View Slides in PDF | |
| 1:42 PM - 1:47 PM | DEBATE: Not So: Why We Should Sometimes Be Raising The Threshold For Treatment In Many Patients |
| Presenter(s):Ross Naylor, MD, FRCS | |
| View Slides in PDF | |
| 1:48 PM - 1:53 PM | How To Promote AAA Sac Thrombosis And Prevent Type 2 Endoleaks After EVAR By Placing Coils In The Lumbar And IMA Branches: Technical Tips |
| Presenter(s):Dominique Fabre, MD | |
| View Slides in PDF | |
| 1:54 PM - 2:00 PM | Panel Discussion |
| END OF SESSION 43 | |
| SESSION 44 SCHEDULE | |
|
Wednesday
SESSION 44:
MORE NEW DEVELOPMENTS RELATING TO AAAs AND EVAR
Moderators:Juan C. Parodi, MD / Daniel G. Clair, MD
|
|
| x | |
| 2:00 PM - 2:05 PM | An Evolution Related Classification System To Help Select The Optimal AAA Endograft For Each EVAR Patient |
| Presenter(s):Claude Mialhe, MD | |
| View Slides in PDF | |
| 2:06 PM - 2:11 PM | High 18 F-FDG Uptake On PET CT In The Aortic Wall Of AAAs Predicts Poor Results Of Treatment And Poor Patient Survival: Why |
| Presenter(s):Natzi Sakalihasan, MD, PhD | |
| View Slides in PDF | |
| 2:12 PM - 2:17 PM | Why Diabetes Is Negatively Associated With AAA Incidence And Growth: A Possible Clue To Medical Treatment Of AAAs |
| Presenter(s):Jes S. Lindholt, MD | |
| View Slides in PDF | |
| 2:18 PM - 2:23 PM | Do New Low Profile EVAR Devices Come At The Cost Of Poorer Durability |
| Presenter(s):Michel Makaroun, MD | |
| View Slides in PDF | |
| 2:24 PM - 2:29 PM | Despite The Declining Incidence Of AAAs, Current AAA Screening Programs Have Value And Save Lives: How Should They Be Structured In 2016 And Beyond |
| Presenter(s):Martin Bjorck, MD, PhD | |
| View Slides in PDF | |
| 2:30 PM - 2:35 PM | DEBATE: On Label Use (Within The IFU) Of Endografts For EVAR Is Key To Achieving Good Results |
| Presenter(s):Andres Schanzer, MD | |
| View Slides in PDF | |
| 2:36 PM - 3:41 PM | DEBATE: Not So: Outcomes For EVAR Using Endografts Outside Their IFU Can Be As Good As Those Within The IFU If Certain Conditions Are Met |
| Presenter(s):Peter L. Faries, MD, FACS | |
| View Slides in PDF | |
| 2:42 PM - 2:47 PM | Risk Assessment And Risk Scores Have Little Value In The EVAR Treatment Of AAAs – In Contrast To Open Treatment |
| Presenter(s):Hence J.M. Verhagen, MD, PhD | |
| View Slides in PDF | |
| 2:48 PM - 2:53 PM | Risk Scoring For Ruptured AAAs Is Of No Value And A Waste Of Time |
| Presenter(s):Janet T. Powell, MD, PhD | |
| View Slides in PDF | |
| 2:54 PM - 2:59 PM | Nellix Endografts (EVAS) Are Useful For Relining And Treating Failed Previous AAA Repairs (Open And Endo): Technique And Results: The Dutch Experience |
| Presenter(s):Barend M.E. Mees, MD, PhD | |
| View Slides in PDF | |
| 3:00 PM - 3:10 PM | Panel Discussion (Refreshments Available In Back Of Room) |
| END OF SESSION 44 | |
| SESSION 45 SCHEDULE | |
|
Wednesday
SESSION 45:
INTERESTING RECORDED LIVE ENDOVASCULAR CASES AND THOSE EMPLOYING NEW AND INNOVATIVE TECHNIQUES
|
|
| x | |
| 3:10 PM - 3:21 PM | Edited Live Case With The Use Of The Zenith Alpha Thoracic Endograft In Conjunction With A 4X Fenestrated Graft In A TAAA |
| Presenter(s):Eric L.G. Verhoeven, MD, PhD | |
| View Slides in PDF | |
| 3:21 PM - 3:32 PM | A New Approach To Calcified Femoral Artery Lesions – Lithoplasty |
| Presenter(s):Andrew Holden, MBChB | |
| View Slides in PDF | |
| 3:32 PM - 3:43 PM | Distal Arteriovenous Fistulas In CLI: The Last Resort |
| Presenter(s):Marco G. Manzi, MD | |
| View Slides in PDF | |
| 3:43 PM - 3:54 PM | Thoracic Aortic Repair After Failed TEVAR |
| Presenter(s):Domenico Baccellieri, MD / Germano Melissano, MD / Roberto Chiesa, MD | |
| View Slides in PDF | |
| 3:54 PM - 4:05 PM | Severe Calcium - One Of The Major Limitations Of Endovascular Therapy: The Role of Lithoplasty - Lessons Learned |
| Presenter(s):Gunnar Tepe, MD | |
| View Slides in PDF | |
| 4:05 PM - 4:16 PM | Aneurysm Formation After Use Of Drug Coated Balloons Following Perforation Of A Degenerative Saphenous Vein Graft |
| Presenter(s):Erwin Blessing, MD | |
| View Slides in PDF | |
| 4:16 PM - 4:27 PM | Long-Term Follow-Up Of Critical Hand Ischemia In Hemodialysis Patients |
| Presenter(s):Roberto Ferraresi, MD | |
| View Slides in PDF | |
| 4:27 PM - 4:37 PM | Panel Discussion |
| END OF SESSION 45 | |
| SESSION 46 SCHEDULE | |
|
Wednesday
SESSION 46:
RECORDED LIVE CASES FROM LEIPZIG AND LINC: REMAINING CHALLENGES AND LATEST INNOVATIONS IN ENDOVASCULAR INTERVENTIONS
Moderators:Dierk Scheinert, MD / Giancarlo Biamino, MD, PhD
|
|
| x | |
| CHALLENGES, CONTROVERSIES, CASES & DISCUSSION | |
| 4:37 PM - 4:45 PM | The Challenge Of Crossing Chronic Total Occlusions: Retrograde Access And CTO Crossing: The Value Of Ultrasound Guidance |
| Presenter(s):Jihad A. Mustapha, MD | |
| View Slides in PDF | |
| 4:46 PM - 5:05 PM | I Do It With X-Ray: Fluoroscopy Guided Tibial Access And Retrograde Recanalization |
| Presenter(s):Andrej Schmidt, MD | |
| View Slides in PDF | |
| 5:05 PM - 5:13 PM | The Challenge Of Calcification: Remove It, Disrupt It Or Go Around It: Update On Innovative Approaches Including Atherectomy, Lithoplasty Or Percutaneous Bypass |
| Presenter(s):Yvonne Bausback, MD | |
| View Slides in PDF | |
| 5:14 PM - 5:33 PM | Just Stent It: Recanalization Of A Severely Calcified Femoropopliteal: Crossing A CTO And High Radial Force Stent Implantation |
| Presenter(s):Andrej Schmidt, MD | |
| View Slides in PDF | |
| 5:33 PM - 5:41 PM | The Challenge Of Restenosis In BTK Arteries: Lessons Learned, Current Projects And Future Concepts For Drug Delivery In BTK Arteries |
| Presenter(s):William A. Gray, MD | |
| View Slides in PDF | |
| 5:42 PM - 6:00 PM | The Stingray Technique: Transcatheter Micropuncture Mediated Adventitial Dexamethasone Infusion For Prevention Of Restenosis: The LIMBO Project |
| Presenter(s):Andrej Schmidt, MD | |
| View Slides in PDF | |
| 6:00 PM - 6:00 PM | End of Program F |
| END OF SESSION 46 | |